Showing results (61-70 of 242) with videos related to
Sort By:
Pageof 25
Biochemical Pharmacology|January 22, 1992
Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cellsR J Riley, P WorkmanCancer Chemotherapy and Pharmacology|January 1, 1986
Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustardsF Y Lee, P WorkmanBritish Journal of Cancer|January 1, 1985
Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNUF Y Lee, P WorkmanEuropean Journal of Cancer (Oxford, England : 1990)|March 11, 2000
Discovering novel chemotherapeutic drugs for the third millenniumM D Garrett, P WorkmanCancer Metastasis Reviews|June 1, 1993
The experimental development of bioreductive drugs and their role in cancer therapyP Workman, I J StratfordBritish Journal of Cancer|May 1, 1984
Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gainF Y Lee, P WorkmanBritish Journal of Cancer|August 1, 1982
Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNUP Workman, P R TwentymanCancer Chemotherapy and Pharmacology|January 1, 1988
Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in miceM I Walton, P WorkmanBiochemical Pharmacology|March 15, 1987
Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitroM I Walton, P WorkmanInternational Journal of Radiation Oncology, Biology, Physics|March 1, 1982
The effect of radiosensitizer pretreatment on the response of the RIF-1 mouse sarcoma to cytotoxic drugsP R Twentyman, P WorkmanPageof 25